KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents (2016 - 2025)

Neogenomics' Cash & Equivalents history spans 16 years, with the latest figure at $159.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 56.51% year-over-year to $159.6 million; the TTM value through Dec 2025 reached $159.6 million, down 56.51%, while the annual FY2025 figure was $159.6 million, 56.51% down from the prior year.
  • Cash & Equivalents reached $159.6 million in Q4 2025 per NEO's latest filing, down from $164.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $612.0 million in Q1 2021 to a low of $154.7 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $310.6 million, with a median of $311.5 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: soared 609.5% in 2021, then plummeted 56.51% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $316.8 million in 2021, then decreased by 16.93% to $263.2 million in 2022, then surged by 30.13% to $342.5 million in 2023, then grew by 7.16% to $367.0 million in 2024, then tumbled by 56.51% to $159.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Cash & Equivalents are $159.6 million (Q4 2025), $164.1 million (Q3 2025), and $154.7 million (Q2 2025).